Thiomersal veterinary grade API is used as an antimicrobial preservative in multi-dose parenteral solutions and emulsions where repeated stopper penetration would otherwise create a microbiological risk. The molecule is sodium ethylmercurithiosalicylate, molar mass 404.81 g/mol, with mercury content of approximately 49.6% by mass. In inactivated viral and bacterial vaccines for companion animals, horses, and poultry where regulatory status permits, the finished product concentration is commonly maintained between 0.005% and 0.010% w/v. Addition is performed after antigen inactivation, purification, and, in alum-adjuvanted products, after adsorption to aluminium hydroxide, because thiomersal can partition onto adjuvant surfaces and reduce the free preservative fraction. The free thiomersal concentration is confirmed after a 24 h equilibration at 2–8 °C by high-performance liquid chromatography with ultraviolet detection at 254 nm. Formulation pH is maintained between 6.5 and 7.5 because alkaline conditions accelerate degradation of the organomercury moiety. Bulk solution is protected from light and processed under low-actinic conditions. Terminal sterile filtration through a 0.22 µm membrane is followed by filling into 10 mL, 20 mL, or 50 mL Type I amber glass vials with bromobutyl rubber closures; elastomer contact is minimised where possible because certain closure materials can deplete thiomersal. The finished multi-dose injection must meet preservative efficacy requirements under USP <51> or Ph. Eur. 5.1.3, and the preservative must comply with 21 CFR 610.15(a) for biological products. Preservative challenge testing includes Staphylococcus aureus ATCC 6538, Pseudomonas aeruginosa ATCC 9027, Escherichia coli ATCC 8739, Candida albicans ATCC 10231, and Aspergillus brasiliensis ATCC 16404. For multi-dose veterinary vaccines, the target bacterial reduction under USP <51> Category 1 is not less than 1.0 log at day 7 and not less than 3.0 log at day 14, with no increase at day 28; yeast and mould counts must show no increase at all three time points.

Table 1 summarises preservative concentration ranges and primary packaging controls across the principal veterinary formulation types.

Do Hyperimmune Serum and Antivenom Batches Require the Same Preservative Load as Vaccines?

Hyperimmune equine serum, polyvalent antivenom, and bovine hyperimmune plasma are filled as multi-dose liquids because emergency protocols may require repeated administration from the same vial under field conditions. Thiomersal is added at 0.005% to 0.010% w/v to the final aqueous formulation after fractionation, sterile filtration, and pH adjustment to 6.5–7.5. These products do not contain aluminium adjuvants, so the main depletion mechanism is adsorption to residual proteins and container surfaces rather than adjuvant partitioning. The preservative demand is therefore established by antimicrobial efficacy testing, not by mercury mass alone. Batch release includes thiomersal assay by cold vapour atomic absorption spectrometry, sterility testing under Ph. Eur. 2.6.1, and antimicrobial preservation testing under Ph. Eur. 5.1.3. The finished vials are stored at 2–8 °C and protected from light; freeze-thaw cycling is avoided because protein aggregation can entrap preservative and reduce the free fraction. Thiomersal is incompatible with fresh serum products requiring intact complement activity because the ethylmercuri moiety binds sulfhydryl groups on complement components. For equine tetanus antitoxin and similar immunobiologicals, the label must state mercury content per dose, and preservative efficacy must be demonstrated throughout the in-use period after first stopper penetration. In the United States, veterinary biological products of this type are subject to 9 CFR 113, and the product licence defines the approved preservative concentration and release tests.

Ophthalmic and intranasal solutions in multi-dose dropper systems

Thiomersal is used at lower concentrations in ophthalmic and intranasal solutions than in parenterals, typically 0.001% to 0.004% w/v, because corneal and mucosal tolerability narrows the usable range. At 0.010% w/v, corneal epithelial cytotoxicity and superficial punctate keratitis have been reported in rabbit ocular irritation models, so higher parenteral concentrations are not transferred to ophthalmic products. Preservative efficacy is established under USP <51> Category 2 or the corresponding Ph. Eur. 5.1.3 criteria for topical and ophthalmic preparations. In practice, the formulation water is nitrogen-sparged to reduce dissolved oxygen, and a chelating agent such as edetate disodium may be included at 0.01% w/v to suppress metal-catalysed degradation. The solution is sterile-filtered through a 0.22 µm polyethersulfone membrane and filled into LDPE dropper bottles or multi-dose dropper tips. Thiomersal is incompatible with polysorbates and with reducing agents such as sodium metabisulfite, which can precipitate elemental mercury or degrade the preservative. Terminal product examples include antimicrobial ophthalmic solutions for dogs, horses, and cats and intranasal liquids for canine infectious respiratory disease, where repeated opening of the dropper justifies a preserved formulation. In such products, the labelling must specify the in-use shelf life after first opening, and preservative efficacy must be retested at the maximum proposed in-use interval.

Allergen extracts and intradermal diagnostic diluents for veterinary dermatology require preservation without interfering with protein allergens. Thiomersal at 0.010% w/v is included in some multi-dose vials used for canine and equine atopic dermatitis panels, often alongside glycerinated saline to reduce evaporative loss and improve protein stability. Because the product is injected intradermally, the negative control must contain the same thiomersal concentration as the allergen vial; otherwise preservative irritancy can produce false-positive wheal-and-flare responses. Compounding is performed at 2–8 °C under low-actinic light, and fill volumes are limited to 5 mL or 10 mL to minimise repeated withdrawal. Preservative efficacy is tested with the representative organisms and acceptance criteria appropriate to the route of administration; for injectable allergen extracts, USP <51> Category 1 criteria apply. Stability data must demonstrate that thiomersal does not precipitate allergenic proteins or alter major allergen content measured by enzyme-linked immunosorbent assay or radial immunodiffusion. If the allergen extract contains phenol or glycerin, the combined preservative system is validated for additive irritancy and osmolality in the intradermal injection vehicle.

When the diluent, not the lyophilised cake, carries the preservative

Freeze-dried inactivated veterinary vaccines and some immunoglobulin preparations are supplied with a separate diluent, and thiomersal is generally added to the diluent rather than to the lyophilised cake. Incorporation into the cake can cause localised concentration gradients during freezing, and the preservative may be lost by adsorption to lyoprotectant matrices or degraded during secondary drying. For inactivated antigen preparations, the diluent is formulated to contain 0.005% to 0.010% w/v thiomersal and is filled as a sterile aqueous solution. Live attenuated vaccines must not be reconstituted with preserved diluents because the organomercury preservative can inactivate the attenuated organism; such products require sterile water or saline without thiomersal. For oral powders, granules, and premixes intended for companion animals, a preserved aqueous reconstitution vehicle may be justified when the dry product is used repeatedly over several days. Dry tablets, capsules, powders, granules, and medicated premixes with water activity below 0.6 do not normally require thiomersal, and direct dry blending of the API into such formats is uncommon because content uniformity at 0.005% w/w is difficult to maintain and organomercury residues in food-producing species are heavily restricted. If a thiomersal-containing solution is used during tablet granulation or capsule filling, the manufacturer must establish content uniformity and demonstrate absence of adsorption to microcrystalline cellulose, starch, dicalcium phosphate, or magnesium stearate. Published data for this specific configuration is limited.

Reassessing topical antiseptic solutions and diagnostic sample fluids

Topical aqueous and tincture preparations containing thiomersal at 0.1% w/v were historically used for pre-surgical skin preparation, umbilical cord antisepsis, and wound irrigation in veterinary practice. Current use is restricted by mercury sensitization and the availability of non-mercurial antiseptics; where formulated, the solution is compounded with ethanol, acetone, and purified water, and stored in amber glass because light exposure degrades the organomercury preservative. Diagnostic laboratory reagents, including red blood cell diluting fluids and immunohaematology diluents, may contain thiomersal at 0.005% to 0.010% w/v to prevent bacterial overgrowth during repeated use. The finished reagent is validated for haemolysis, agglutination interference, and matrix effects because organomercury compounds can bind erythrocyte membrane sulfhydryl groups. Preservative efficacy is confirmed under the relevant compendial category, and the label must state mercury content per millilitre or per dose. In food-producing animals, the use of thiomersal in any dosage form must be justified against current maximum residue limit regulations, and withdrawal periods must be established where required by the competent authority.